Skip to main content

Fluorotechnics Q2 Revenues Drop to $129K

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluorotechnics last week reported that second-quarter revenues from customers had dropped to A$119,189 ($129,151), down from A$1.9 million ($2.1 million) a year ago.

For the quarter ended June 30, R&D expenses were sliced to A$9,425 from $264,231 a yaer ago, while SG&A spending dropped to A$1,169 from A$354,777.

Net operating cash flows came in at a loss of A$87,601, down from a loss of A$1.6 million in the second quarter of 2010.

As of June 30, the Australian fluorescence and protein detection technologies firm had A$189,278 in cash.

The company is in the midst of a restructuring effort that includes the scaling back of its operations and sale of certain of its assets. Ian Gilmour, Fluorotechnic's secretary, said in a note that the company is continuing the process "for the orderly sale of the remaining operations and assets."

He added that the company "is continuing to review new investment opportunities."

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.